Latest Ratios: P/E Ratio -0.0x · EV/EBITDA N/A · ROE -392.4%. (2019–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $1207 | $23491 | $5M | $11M | $7M | $53M | — | — |
| Enterprise Value | $3M | $3M | $8M | $14M | $8M | $55M | — | — |
| P/E Ratio → | -0.00 | — | — | — | — | — | — | — |
| P/S Ratio | 0.00 | 0.00 | 0.44 | 0.34 | 0.14 | 1.50 | — | — |
| P/B Ratio | 0.00 | 0.00 | — | — | 1.09 | 3.28 | — | — |
| P/FCF | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.23 | 0.67 | 0.42 | 0.17 | 1.55 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 13.6% | 13.6% | 24.7% | 20.4% | 24.6% | 29.8% | 24.8% | 17.7% |
| Operating Margin | -70.5% | -70.5% | -40.6% | -23.2% | -35.6% | -15.2% | 3.8% | 5.8% |
| Net Profit Margin | -68.2% | -68.2% | -51.0% | -26.2% | -31.3% | -16.9% | 7.5% | 4.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | -392.4% | -392.4% | — | -373.7% | -129.5% | -58.1% | 74.7% | 59.3% |
| ROA | -76.7% | -76.7% | -135.4% | -86.3% | -75.8% | -33.3% | 24.3% | 14.2% |
| ROIC | -138.9% | -138.9% | — | -133.5% | -97.1% | -37.4% | 37.7% | 125.2% |
| ROCE | -405.3% | -405.3% | — | -286.5% | -130.4% | -47.2% | 36.9% | 81.3% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.08 | 1.08 | — | — | 0.44 | 0.21 | 0.17 | — |
| Debt / EBITDA | — | — | — | — | — | — | 0.38 | — |
| Net Debt / Equity | — | 0.31 | — | — | 0.22 | 0.10 | -0.15 | -0.49 |
| Net Debt / EBITDA | — | — | — | — | — | — | -0.33 | -0.40 |
| Debt / FCF | — | — | — | — | — | — | — | -0.25 |
| Interest Coverage | -17.26 | -17.26 | -3.91 | -7.94 | -64.34 | -9.45 | 14.96 | 31.75 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.03 | 1.03 | 0.21 | 0.69 | 1.22 | 1.89 | 1.18 | 0.85 |
| Quick Ratio | 1.03 | 1.03 | 0.21 | 0.69 | 1.22 | 1.89 | 1.18 | 0.85 |
| Cash Ratio | 0.60 | 0.60 | 0.00 | 0.15 | 0.20 | 0.28 | 0.21 | 0.16 |
| Asset Turnover | — | 0.61 | 5.96 | 4.84 | 3.46 | 1.43 | 2.82 | 3.48 |
| Inventory Turnover | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 54.39 | 34.64 | 39.52 | 46.65 | 100.09 | 74.50 | 52.97 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 2.1% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 2.1% | 0.0% | — | — |
| Shares Outstanding | — | $619 | $353 | $280 | $248 | $197 | $236 | $236 |
Liquidity and capital exhaustion
As reported in recent financial statements, HCTI's gross margin of 16.1% in 2026Q1 highlights a service-heavy cost structure that fails to provide the operating leverage necessary to offset significant R&D and SG&A expenses, resulting in a deeply negative operating margin of -36.8% for the period.
The inability to expand gross margins beyond the mid-teens suggests that the company's revenue is primarily driven by low-margin professional services rather than high-margin software subscriptions. Investors should monitor whether the firm can transition its revenue mix toward proprietary platforms, as current profitability metrics indicate a business model that is structurally challenged by high variable labor costs.
Based on historical financial data, HCTI's ROIC has remained consistently negative, reaching -7.5% in 2026Q1, which indicates that the company is currently destroying shareholder value rather than compounding it through its investments in cloud and data science infrastructure.
The persistent negative returns on invested capital suggest that management has not yet identified a path to profitable growth, with returns significantly lagging behind industry peers. This trend warrants further investigation into whether the company's capital allocation strategy is focused on sustainable growth or merely sustaining operations through continuous, dilutive financing.
According to quarterly filings, HCTI's DSO has fluctuated significantly, reaching 54 days in 2026Q1, which reflects an inconsistent ability to collect on service contracts and suggests potential friction in the company's cash conversion cycle compared to more mature healthcare IT service providers.
The erratic nature of the company's working capital management, combined with a current ratio that has dipped to 0.90, implies that liquidity is highly sensitive to the timing of client payments. This lack of efficiency in managing receivables may exacerbate the company's existing cash burn, leaving little room for operational errors.
As evidenced by the 2026Q1 balance sheet, the current ratio of 0.90 indicates that HCTI's short-term assets are insufficient to cover its immediate liabilities, a precarious position that leaves the firm highly vulnerable to any disruption in its project-based revenue streams or access to external capital.
The reliance on external financing to maintain operations is underscored by the company's limited cash reserves relative to its ongoing operating losses. Investors should be wary of the potential for further equity dilution, as the current liquidity profile appears inadequate to support the company's long-term strategic objectives without significant capital intervention.
Market participants frequently misapply SaaS-based valuation multiples to HCTI, failing to recognize that the company's 16.1% gross margin is more characteristic of a low-margin IT consultancy than a high-margin software platform, which obscures the true risk profile of the business.
Valuing HCTI as a high-growth software firm ignores the reality that its revenue is heavily tied to labor-intensive implementation services. Analysts should instead focus on service-based metrics such as utilization rates and contract profitability, as the current valuation narrative appears disconnected from the company's actual financial performance and cost structure.
Includes 30+ ratios · 7 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying HCTI stock.
Healthcare Triangle, Inc.'s current P/E ratio is -0.0x. This places it at the 50th percentile of its historical range.
Healthcare Triangle, Inc.'s return on equity (ROE) is -392.4%. The historical average is -136.6%.
Based on historical data, Healthcare Triangle, Inc. is trading at a P/E of -0.0x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Healthcare Triangle, Inc. has 13.6% gross margin and -70.5% operating margin.